Granulomatous Disease, Chronic
A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern.
Drugs by status
Approved for this indication (1)
Phase 4 trials (1)
Phase 3 trials (3)
Phase 2 trials (31)
- plerixafor
- busulfan
- tofacitinib
- Pegfilgrastim
- Filgrastim
- palifermin
- allogeneic hematopoietic stem cells
- sirolimus
- cyclosporine
- cyclophosphamide
- stem cells
- tocilizumab
- vm106
- autologous cd34+ cells
- x-cgd-gene-corrected autologous cd34+ cells
- lentiviral g1xcgd
- infliximab
- pcclchimgp91s lentiviral vector transduced cd34+ cells
- retroviral sf71-gp91phox transduced cd34+ cells
- x vivo gene therapy
- fludarabine
- pioglitazone
- thiotepa
- melphalan
- emapalumab-lzsg
- autologous hematopoietic stem cells
- il2rg gene into the blood forming stem cells (cd34+ cells)
- base-edited hematopoietic stem and progenitor cells
- cells transduced with pcclchim-p47
- pm359
- +1 more
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (27)
- Genethon
- Fondazione Telethon
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- University of Pittsburgh
- Baylor University
- University of London
- Harvard University
- Medical College of Wisconsin
- Radboud University
- Seoul National University
- Stanford University
- University of Florida
- University of Southern California
- University of Zurich
- University of California, Los Angeles
- State University of New York, Buffalo
- Vita-Salute University of Milano. Italy
- University of Paris
- J. W. Goethe University
- Washington University in St. Louis
- California Institute for Regenerative Medicine
- Blood and Marrow Transplant Clinical Trials Network
- German Federal Ministry of Education and Research
- ViroMed
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (3)